Are apixaban, dabigatran, and rivaroxaban cost-effective alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation?
Novel oral anticoagulants (apixaban, dabigatran, and rivaroxaban) are cost-effective alternatives to warfarin for stroke prevention in atrial fibrillation within the US healthcare context.
In patients with nonvalvular atrial fibrillation and an increased risk of stroke prophylaxis, apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg were all cost-effective alternatives to warfarin. The cost-effectiveness of novel oral anticoagulantss was dependent on therapy pricing in the United States and neurological events associated with rivaroxaban 20 mg.
Harrington et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: